Altos Labs vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Altos Labs is a longevity biotech company focused on cellular rejuvenation programming to reverse disease and extend healthspan; raised $3B at launch in 2022 backed by Jeff Bezos and Yuri Milner;
About
Altos Labs is a biotechnology company incorporated in 2021 and publicly launched in January 2022 with an extraordinary $3 billion Series A — the largest biotech launch funding round in history. The company is backed by Jeff Bezos and Yuri Milner, among others, and is headquartered in San Carlos, California, with research institutes in Cambridge, UK, and Japan. Altos Labs is focused on biological reprogramming and cellular rejuvenation — the scientific field exploring whether Yamanaka factors (a set of transcription factors that can reset a cell's epigenetic age) can be applied therapeutically to reverse disease progression and restore cellular function in aging tissues without causing cancer or loss of cell identity.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.